

BODY MASS INDEX MAY BE THE MAJOR DETERMINING FACTOR OF PLASMA CHOLESTEROL VALUES

Mehmet Rami Helvaci (1)

Mustafa Yaprak (1)

Atilla Yalcin (1)

Orhan Ekrem Muftuoglu (1)

Abdulrazak Abyad (2)

Lesley Pocock (3)

(1) Specialist of Internal Medicine, MD

(2) Middle-East Academy for Medicine of Aging, MD

(3) medi-WORLD International

Corresponding author:

Prof Dr Mehmet Rami Helvaci,

ALANYA, Antalya, Turkey

Phone: 00-90-506-4708759

Email: mramihelvaci@hotmail.com

Received: December 2020; Accepted: January 2021; Published: February 1, 2021

Citation: Mehmet Rami Helvaci et al. Body mass index may be the major determining factor of plasma cholesterol values. Middle East Journal of Nursing 2021; 15(1): 18-24. DOI: 10.5742/MEJN2021.93798

Abstract

Background: We tried to understand possible effects of sickle cell diseases (SCD) on metabolic parameters including cholesterol values in the plasma.

Methods: All patients with the SCD and age and gender-matched control cases were included into the study.

Results: We studied 363 patients with the SCD (194 males) and 255 control cases (136 males), totally. Mean ages of the SCD patients were similar in males and females (31.1 versus 31.0 years, respectively, $p>0.05$). Although the body weight and body mass index (BMI) were significantly suppressed in the SCD patients (59.9 versus 71.5 kg and 21.9 versus 25.6 kg/m², respectively, $p=0.000$ for both), the body heights were similar in both groups (164.9 versus 167.0 cm, $p>0.05$). Parallel to the suppressed mean body weight and BMI, fasting plasma glucose (92.8 versus 97.6 mg/dL, $p=0.005$), total cholesterol (TC) (121.4 versus 165.0 mg/dL, $p=0.000$), low density lipoproteins (LDL) (70.4 versus 102.4 mg/dL, $p=0.000$), and high density lipoproteins (HDL) (26.0 versus 39.6 mg/dL, $p=0.000$) values were all suppressed in the SCD

patients, significantly. Similarly, both systolic (115.2 versus 122.6 mmHg, $p=0.000$) and diastolic blood pressure (73.0 versus 86.6 mmHg, $p=0.000$) were also suppressed in them, significantly. Interestingly, only the plasma triglycerides were increased in the SCD patients (129.4 versus 117.3 mg/dL, $p=0.000$), significantly. Similarly, mean alanine aminotransferase value was not suppressed in them, too (27.4 versus 27.3 U/L, $p>0.05$).

Conclusion: The BMI may be the major determining factor of TC, LDL, and HDL values in the plasma.

Key words: Body mass index, total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, metabolic syndrome, sickle cell diseases

Introduction

Chronic endothelial damage may be the major underlying cause of aging and death by causing disseminated atherosclerosis and end-organ failures in human being (1, 2). Much higher blood pressure (BP) of the afferent vasculature may be the major underlying factor by causing recurrent injuries on vascular endothelium. Probably, whole afferent vasculature including capillaries are mainly involved in the process. Therefore the term of venosclerosis is not as famous as atherosclerosis in the literature. Due to the chronic endothelial damage, inflammation, edema, and fibrosis, vascular walls thicken, their lumens narrow, and they lose their elastic natures, those eventually reduce blood supply to the terminal organs, and increase systolic BP further. Some of the well-known triggering causes or signs of the inflammatory process are sedentary lifestyle, physical inactivity, animal-rich diet, smoking, alcohol, overweight, hypertriglyceridemia, dyslipidemia, impaired fasting glucose, impaired glucose tolerance, white coat hypertension, chronic inflammations, prolonged infections, and cancers for the development of terminal consequences including obesity, hypertension (HT), diabetes mellitus (DM), cirrhosis, chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), chronic renal disease (CRD), peripheral artery disease (PAD), mesenteric ischemia, osteoporosis, stroke, dementia, various end-organ insufficiencies, aging, and death (3, 4). Although early withdrawal of the triggering causes can delay terminal consequences, after development of the terminal consequences, endothelial changes can not be reversed completely due to their fibrotic natures. The triggering causes and terminal consequences are researched under the titles of metabolic syndrome, aging syndrome, or accelerated endothelial damage syndrome in the literature, extensively (5, 6). On the other hand, sickle cell diseases (SCD) are chronic inflammatory process on vascular endothelium terminating with accelerated atherosclerosis induced end-organ failures and shortened survivals in both genders (7, 8). Hemoglobin S (Hb S) causes loss of elastic and biconcave disc shaped structures of red blood cells (RBC). Probably loss of elasticity instead of shape is the main problem because sickling is rare in peripheral blood samples of patients with associated thalassemia minors, and human survival is not affected in hereditary spherocytosis or elliptocytosis. Loss of elasticity is present during whole lifespan, but exaggerated with inflammations, infections, and various stresses of the body. The hard RBC induced chronic endothelial damage, inflammation, edema, and fibrosis terminate with disseminated tissue hypoxia all over the body (9, 10). As a difference from other causes of chronic endothelial damage, the SCD may keep vascular endothelium particularly at the capillary level (11), since the capillary system is the main distributor of the hard cells into the tissues. The hard RBC induced chronic endothelial damage builds up an advanced atherosclerosis in much younger ages of the patients. Vascular narrowings and occlusions induced tissue ischemia and infarctions are the final consequences of the SCD, so the mean life expectancy is decreased by 25 to 30 years in the SCD patients (12). Actually, the SCD and metabolic syndrome may have similar pathophysiologic effects on human body,

and SCD are a chance for us that we can see several consequences of metabolic syndrome on human body in much earlier ages of the patients. We tried to understand possible effects of the SCD on metabolic parameters including cholesterol values in the plasma.

Material and methods

The study was performed in the Medical Faculty of the Mustafa Kemal University on all patients with the SCD and age and gender-matched control cases between March 2007 and June 2016. The SCD are diagnosed with the hemoglobin electrophoresis performed via high performance liquid chromatography. Medical histories of the SCD patients were learnt. A complete physical examination was performed by the Same Internist. Body mass index (BMI) of each case was calculated by the measurements of the Same Internist instead of the verbal expressions. Weight in kilogram is divided by height in meter squared (13). Systolic and diastolic BP were checked after a 5-minute of rest in seated position by using the mercury sphygmomanometer (ERKA, Germany), and no smoking was permitted during the previous 2-hour. Cases with acute painful crisis or any other inflammatory event were treated at first, and the laboratory tests and clinical measurements were performed on the silent phase. A check up procedure including fasting plasma glucose (FPG), total cholesterol (TC), high density lipoproteins (HDL), triglycerides (TG), serum creatinine, alanine aminotransferase (ALT), markers of hepatitis viruses A, B, C and human immunodeficiency virus, a posterior-anterior chest x-ray film, and an electrocardiogram was performed. Eventually, the mean body weight, height, BMI, FPG, TC, low density lipoproteins (LDL), HDL, TG, ALT, and systolic and diastolic BP were detected in each group, and compared in between. Mann-Whitney U Test, Independent-Samples t Test, and comparison of proportions were used as the methods of statistical analyses.

Results

The study included 363 patients with the SCD (194 males) and 255 control cases (136 males), totally. The mean ages of the SCD patients were similar in males and females (31.1 versus 31.0 years, respectively, $p>0.05$). Although the mean body weight and BMI were significantly suppressed in the SCD patients (59.9 versus 71.5 kg and 21.9 versus 25.6 kg/m², respectively, $p=0.000$ for both), the mean body heights were similar in both groups (164.9 versus 167.0 cm, $p>0.05$). Parallel to the suppressed mean body weight and BMI, FPG (92.8 versus 97.6 mg/dL, $p=0.005$), TC (121.4 versus 165.0 mg/dL, $p=0.000$), LDL (70.4 versus 102.4 mg/dL, $p=0.000$), and HDL (26.0 versus 39.6 mg/dL, $p=0.000$) were all suppressed in the SCD patients, significantly. Similarly, both systolic (115.2 versus 122.6 mmHg, $p=0.000$) and diastolic BP (73.0 versus 86.6 mmHg, $p=0.000$) were also suppressed in them, significantly. Interestingly, only the plasma TG were increased in the SCD patients (129.4 versus 117.3 mg/dL, $p=0.000$), significantly. Similarly, mean ALT value was not suppressed in them, too (27.4 versus 27.3 U/L, $p>0.05$) (Table 1).

Table 1: Characteristic features of the study cases

Variables	Patients with SCD*	p-value	Control cases
Number	363		255
Age (year)	31.0 ± 9.2 (17-59)	Ns†	31.2 ± 8.6 (16-45)
Male ratio	53.4% (194)	Ns	53.3% (136)
<u>Body weight</u> (kg)	<u>59.9 ± 11.8 (30-122)</u>	<u>0.000</u>	<u>71.5 ± 16.4 (40-128)</u>
Body height (cm)	164.9 ± 9.1 (142-194)	Ns	167.0 ± 8.6 (147-192)
<u>BMI‡</u> (kg/m ²)	<u>21.9 ± 3.6 (14.3-46.4)</u>	<u>0.000</u>	<u>25.6 ± 5.8 (15.8-53.5)</u>
<u>FPG§</u> (mg/dL)	<u>92.8 ± 12.5 (57-125)</u>	<u>0.005</u>	<u>97.6 ± 19.7 (66-269)</u>
<u>TC </u> (mg/dL)	<u>121.4 ± 32.2 (65-296)</u>	<u>0.000</u>	<u>165.0 ± 54.3 (72-510)</u>
<u>LDL¶</u> (mg/dL)	<u>70.4 ± 28.4 (20-270)</u>	<u>0.000</u>	<u>102.4 ± 41.1 (29-313)</u>
<u>HDL**</u> (mg/dL)	<u>26.0 ± 9.4 (4-60)</u>	<u>0.000</u>	<u>39.6 ± 13.2 (7-95)</u>
<u>TG***</u> (mg/dL)	<u>129.4 ± 90.4 (31-1216)</u>	<u>0.000</u>	<u>117.3 ± 107.4 (24-931)</u>
ALT**** (U/L)	27.4 ± 16.2 (4-118)	Ns	27.3 ± 21.6 (6-117)
<u>Systolic BP*****</u> <u>(mmHg)</u>	<u>115.2 ± 15.7 (80-190)</u>	<u>0.000</u>	<u>122.6 ± 19.4 (80-200)</u>
<u>Diastolic BP</u> <u>(mmHg)</u>	<u>73.0 ± 12.3 (50-120)</u>	<u>0.000</u>	<u>86.6 ± 13.6 (60-120)</u>

*Sickle cell diseases †Nonsignificant (p>0.05) ‡Body mass index §Fasting plasma glucose ||Total cholesterol ¶Low density lipoproteins **High density lipoproteins ***Triglycerides ****Alanine aminotransferase *****Blood pressure

Discussion

Cholesterol, TG, and phospholipids are the major lipids of the body. Actually, cholesterol is a waxy substance that is classified as a steroid. It is synthesized by the liver, adrenal glands, reproductive organs, and intestines according to the body needs. It plays a central role in many biochemical processes in human body. For example, it is an essential structural component of animal cell membrane, bile acids, adrenal and gonadal steroid hormones, and vitamin D. Cholesterol crystallizes in the gall bladder and forms the major constituent of most gallstones. Cholesterol is oxidized by the liver into a variety of bile acids. These, in turn, are conjugated. A mixture of conjugated and nonconjugated bile acids, along with cholesterol itself, is excreted from the liver into the bile. Approximately, 95% of the bile acids are reabsorbed from the intestines. By this way 50% of the excreted cholesterol is reabsorbed by the small bowel into the bloodstream again. The excretion and reabsorption of bile acids forms the basis of the enterohepatic circulation, which is essential for digestion and absorption of dietary fats. Cholesterol is kept in balance by homeostatic mechanisms in human body, and cholesterol biosynthesis is directly regulated by the cholesterol levels present. The higher dietary intake leads to reduced synthesis whereas lower dietary intake leads to increased synthesis of cholesterol in the body. Additionally, most of dietary cholesterol is esterified, and esterified cholesterol is poorly absorbed in the body. For these reasons, dietary cholesterol has little effect on plasma cholesterol values. On the other hand, when the cell has abundant cholesterol, LDL receptor

synthesis is blocked so new cholesterol in the form of LDL molecules cannot be taken up. On the converse, more LDL receptors are made when the cell is deficient in cholesterol. Cholesterol is found only in foods that come from animals but not in fruits, vegetables, cereals, nuts, and other plants. On the other hand, TG are the fat found in our foods. Most of the fat in the human body is stored in the form of TG again. Calories not burned by the body are automatically converted into TG, which explains why eating too much of anything can lead to excess weight. Fatty acids in stored TG can be removed and used to provide energy for muscles. On the other hand, when stored by the body, TG help to protect and insulate internal organs and cushion the blow of a fall. Actually, the number of fat cells in the body does not fluctuate along with changes in weight instead the fat cells themselves get bigger or smaller. Additionally, TG are the major lipids transported in the blood. In another word, TG provide energy for muscles, are stored as body fat, and are used to produce LDL in the body. TG are composed of even smaller units of fat called as fatty acids that are attached to a chemical base of glycerol. Fatty acids are known as the building blocks of fat. Fatty acids are described as saturated, polyunsaturated, or monounsaturated depending on how much hydrogen they contain. Saturated fatty acids contain the most hydrogen, and they are considered as the most dangerous ones for the health. Interestingly, along with the cholesterol we get from foods, saturated fats can raise the blood cholesterol levels more than anything else in the foods. Saturated fats may increase blood cholesterol levels by slowing down the removal of LDL. Therefore, blood cholesterol values may increase even if the diet

values may increase even if the diet is rich for saturated fats but poor for cholesterol. Foods containing saturated fats mainly come from animals, too. These foods also contain too much cholesterol actually, so they can raise blood cholesterol levels in two ways at the same time. Phospholipids are TG that are covalently bound to a phosphate group. Phospholipids regulate membrane permeability, remove cholesterol from the body, provide signal transmission across the membranes, act as detergents, and help in solubilization of cholesterol.

Cholesterol, TG, and phospholipids do not circulate freely in the plasma instead they are bound to proteins, and transported as lipoproteins. There are five major classes of lipoproteins including chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), LDL, and HDL in the plasma. They are classified by their density of protein. The lower the protein, the less dense it is, the higher the cholesterol. The cholesterol within all the various lipoproteins is identical. In another word, there is really only one kind of cholesterol in the body. Chylomicrons are the least dense types of cholesterol transport molecules. Chylomicrons are made of TG, cholesterol, and protein in the intestines, and released into the bloodstream after a meal. Chylomicrons mainly carry exogenous TG from the intestine to the liver via the thoracic duct. VLDL also contains TG, cholesterol, and protein. VLDL are produced in the liver, and mainly carry endogenous TG from the liver to the peripheral organs. In the capillaries of adipose and muscle tissues, 90% of TG is removed by a specific group of lipases. So VLDL are converted into IDL by removal of TG. Then IDL are degraded into LDL by removal of more TG. So VLDL are the main sources of LDL in the plasma. LDL are the major carriers of cholesterol in the blood. LDL deliver cholesterol from the liver to other parts of the body. Although the liver removes majority of LDL from the circulation, a small amount is uptaken by macrophages those may migrate into the inner intima layer of arterial walls and become the foam cells of atherosclerotic plaques. The foam cells are filled with fat and cholesterol. They make up most of plaques. The plaques contain mainly cholesterol, calcium, fibrin, and cellular debris. This process may be accelerated when LDL become oxidized by free oxygen radicals that are produced as a byproduct while our cells are using oxygen to burn fat. Remnants of chylomicrons and VLDL may be able to deposit cholesterol onto artery walls in the same manner with LDL. When TG values are high, there is a larger number of these remnants in the plasma, and a greater risk that arteries are being exposed to their LDL-like effects. Cholesterol that reaches the intima by way of these remnants may be used to produce new foam cells, and that results in more artery-clogging plaque. These remnants may also be vulnerable to oxidation, in which case they pose an even greater threat. Over time these hard deposits thicken the wall of the arteries, forcing blood to squeeze through a narrower space. HDL remove fats and cholesterol from cells including within arterial wall atheroma, and carry the cholesterol back to the liver, adrenals, ovaries, and testes for excretion, reutilization, or disposal. All of the carrier lipoproteins

are under dynamic control in the plasma, and are readily affected by diet, illness, drug, and BMI. Thus lipid analysis should be performed during a steady state. But the metabolic syndrome alone is a low grade inflammatory process on vascular endothelium and may be a cause of the abnormal lipoproteins levels in the plasma. Similarly, due to the severe inflammatory nature of the SCD, plasma TC (121.4 versus 165.0 mg/dL, $p<0.000$) and LDL values (70.4 versus 102.4 mg/dL, $p<0.000$) were suppressed parallel to the suppressed body weight (59.9 versus 71.5 kg, $p<0.000$) and BMI (21.9 versus 25.6 kg/m², $p<0.000$) in the present study. On the other hand, although HDL are commonly called as 'the good cholesterol' due to their roles in removing excess cholesterol from the blood and protecting the arterial walls against atherosclerosis (14), recent studies did not show similar results. Instead low HDL values should alert clinicians about searching of additional metabolic or inflammatory pathologies in human body (15, 16). Normally, HDL may show various anti-atherogenic properties including reverse cholesterol transport and anti-oxidative and anti-inflammatory properties (15). However, HDL may become 'dysfunctional' in pathologic conditions which means that relative compositions of lipids and proteins, as well as the enzymatic activities of HDL are altered (15). For example, properties of HDL are compromised in patients with DM due to the oxidative modification and glycation as well as the transformation of HDL proteomes into proinflammatory proteins. Additionally, the highly effective agents of increasing HDL levels such as niacin, fibrates, and cholesteryl ester transfer protein inhibitors did not reduce all cause mortality, CHD mortality, myocardial infarction, or stroke (17). While higher HDL levels are correlated with cardiovascular health, medications used to increase HDL did not improve the health (17). In another word, while high HDL levels may correlate with better cardiovascular health, specifically increasing one's HDL values may not increase cardiovascular health (17). So they may just be some indicators instead of being the main actors of the human health. Similarly, BMI, FPG, DM, and CHD were the lowest between the HDL values of 40 and 46 mg/dL, and the prevalence DM was only 3.1% between these values against 22.2% outside of these limits (18). In another definition, the moderate HDL values may also be the results instead of causes of the better human health status. Similarly, plasma HDL value was suppressed significantly (39.6 versus 26.0 mg/dL, $p<0.000$) parallel to the suppressed body weight and BMI in the patients, probably due to the severe inflammatory nature of the SCD in the present study.

BP is the force that blood exerts on the elastic walls of arteries. Higher BP indicates that heart and blood vessels are being overworked. In most people with HT, increased peripheral vascular resistance accounts for HT while cardiac output remains normal (19). The increased peripheral vascular resistance is mainly attributable to structural narrowing of small arteries and arterioles, although a reduction in the number of capillaries may also contribute (20). HT is more common in patients with sedentary lifestyle, obesity, alcoholism, and associated

diseases such as DM, CRD, and COPD (21). HT is rarely accompanied by symptoms in short-term. Symptoms attributed to HT in that period may actually be related with associated anxiety rather than HT itself. However, HT may be the major risk factor for CRD, cirrhosis, COPD, stroke, dementia, and PAD-like end-organ insufficiencies in long-term since it damages the inner linings of arteries and sets the stage for atherosclerosis. Plaque deposits are more likely to develop in the areas of damage. If untreated, HT can also increase the heart's workload terminating with CHD. For example, a reduction of the BP by 5 mmHg can decrease the risk of stroke by 34% and CHD by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular diseases (22). On the other hand, we can not detect any absolute cause in majority of patients with HT. Physical inactivity, sedentary lifestyle, animal-rich diet, excess weight, smoking, alcohol, chronic inflammations, prolonged infections, and cancers may be found among the possible risk factors of HT. Particularly, excess weight may be the major underlying cause of HT in the world, now. Adipose tissue produces leptin, tumor necrosis factor- α , plasminogen activator inhibitor-1, and adiponectin-like cytokines, acting as acute phase reactants in the plasma (23). Excess weight-induced chronic low-grade vascular endothelial inflammation may play a significant role in the pathogenesis of accelerated atherosclerosis in human body (24). Additionally, excess weight leads to myocardial hypertrophy terminating with a decreased cardiac compliance. Combination of these cardiovascular risk factors eventually terminate with increased risks of arrhythmias, cardiac failure, and sudden death. Similarly, the prevalences of CHD and stroke increased parallel to the increased BMI in the other studies (25, 26), and risk of death from all causes including cancers increased throughout the range of moderate to severe weight excess in all age groups (27). The relationship between excess weight, elevated BP, and hypertriglyceridemia is described in the metabolic syndrome (28). Similarly, prevalences of excess weight, DM, HT, and smoking were all higher in the hypertriglyceridemia group (200 mg/dL and higher) in another study (29). Carbon monoxide in cigarette smoke damages the smooth inner surface of arteries. This damage encourages the buildup of plaque on artery walls and makes them hard and narrow. The carbon monoxide molecules hitch a ride on RBC, occupying valuable space that is normally reserved for the oxygen on which the human body depends. In addition to narrowing arteries and taking the place of oxygen in the body, cigarette smoke thickens the blood itself by boosting levels of fibrinogen. Furthermore, smoking may also reduce levels of HDL in the plasma probably due to the systemic inflammatory effects on vascular endothelium. On the other hand, the greatest number of deteriorations in the metabolic parameters was observed just above the plasma TG value of 60 mg/dL in another study (30). Interestingly, plasma TG were the only lipids those were not suppressed instead increased parallel to the suppressed body weight and BMI in the SCD patients in the present study.

SCD are hereditary hemolytic anemias characterized by the presence of Hb S. Hb S causes RBC to change their normal biconcave disc shape to a sickle shape under the effects of various stresses. The RBC can take their normal shapes after normalization of the stressful conditions, but after repeated cycles of sickling and unsickling, hemolysis occurs. So lifespan of the RBC decreases from the normal 120 days to 15-25 days. The chronic hemolytic anemia is mainly responsible for the anemia that is the hallmark of the SCD. Painful crises are the most disabling symptoms of the SCD. Although painful crises may not be life threatening directly (31), infections are the most common triggering factors of them. So the risk of mortality is significantly higher during the crises. On the other hand, the severe pain may be the result of complex interactions between RBC, white blood cells (WBC), platelets (PLT), and endothelial cells. Probably, leukocytosis contributes to the pathogenesis by releasing several cytotoxic enzymes. The adverse actions of WBC and PLT on the endothelial cells are of particular interest with regard to the stroke and cerebrovascular diseases in the SCD (32). For example, leukocytosis in the absence of any infection was an independent predictor of the severity of the SCD (33), and it was associated with an increased risk of stroke (34). Occlusions of vasculature of the bone marrow, bone infarctions, inflammatory mediators, and activation of afferent nerves may take role in the pathophysiology of the severe pain. Due to the severity of pain, narcotic analgesics are generally used during the attacks. Due to the repeated infarctions and subsequent fibrosis, the spleen is usually too small in adults. Eventually, a functional and anatomic asplenism develops due to the decreased antibody production, prevented opsonization, and reticuloendothelial dysfunction. Terminal consequence of the asplenism is an increased risk of infections with *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis*-like encapsulated bacteria. Particularly, pneumococcal infections are so common in early childhood with higher mortality rates. The causes of death were infections in 56% of infants in a previous study (33). In another study, the peak incidence of death among children occurred between 1 and 3 years of age, and the deaths under the age of 20 years were predominantly caused by pneumococcal sepsis (35). Adult patients, even those who appear relatively fit, are susceptible to sepsis, multiorgan failures, and sudden death during acute painful crises due to the severe and prolonged inflammatory process initiated at birth in them (36, 37). SCD can affect all vascular organ systems of the body (38, 39). Aplastic crises, sequestration crises, hemolytic crises, acute chest syndrome, avascular necrosis of the femoral and humeral heads, priapism and infarction of the penis, osteomyelitis, acute papillary necrosis of the kidneys, CRD, occlusions of retinal arteries and blindness, pulmonary HT, bone marrow necrosis induced dactylitis in children, chronic punched-out ulcers around ankles, hemiplegia, and cranial nerve palsies are only some of the several presentation types. Eventually, the median ages of death were 42 years in males and 48 years in females in the literature (12). Delayed initiation of hydroxyurea therapy and inadequate RBC supports during medical or surgical

procedures may decrease the expected survival further (40). Actually, RBC supports must be given immediately during all medical or surgical emergencies in which there is an evidence of clinical deterioration (41). RBC supports decrease sickle cell concentration in the circulation and suppress bone marrow for the production of abnormal RBC. So it decreases sickling-induced endothelial damage and inflammation in whole body. Due to the great variety of clinical presentation types, it is not surprising to see that the mean weight and BMI were significantly suppressed in patients with the SCD ($p < 0.000$ for both) in the present study. Probably due to the significantly suppressed body weight and BMI, mean values of the FPG, TC, LDL, HDL, systolic BP, and diastolic BP were also suppressed in the SCD, which can be explained by definition of the metabolic syndrome (42, 43). On the other hand, the non-suppressed ALT value may indicate the hepatic involvement in them (44).

As a conclusion, BMI may be the major determining factor of TC, LDL, and HDL values in the plasma.

References

- Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003; 42(7): 1149–1160.
- Helvacı MR, Seyhanlı M. What a high prevalence of white coat hypertension in society! *Intern Med* 2006; 45(10): 671–674.
- Helvacı MR, Kaya H, Seyhanlı M, Yalcin A. White coat hypertension in definition of metabolic syndrome. *Int Heart J* 2008; 49(4): 449–457.
- Helvacı MR, Sevinc A, Camci C, Yalcin A. Treatment of white coat hypertension with metformin. *Int Heart J* 2008; 49(6): 671–679.
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; 365(9468): 1415–1428.
- Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. *J Hypertens* 2006; 24(10): 2009–2016.
- Helvacı MR, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatosteatosis in sickle cell diseases. *World Family Med* 2018; 16(3): 12–18.
- Helvacı MR, Davarci M, Inci M, Yaprak M, Abyad A, Pocock L. Chronic endothelial inflammation and priapism in sickle cell diseases. *World Family Med* 2018; 16(4): 6–11.
- Helvacı MR, Gokce C, Davran R, Akkucuk S, Ugur M, Oruc C. Mortal quintet of sickle cell diseases. *Int J Clin Exp Med* 2015; 8(7): 11442–11448.
- Helvacı MR, Kaya H. Effect of sickle cell diseases on height and weight. *Pak J Med Sci* 2011; 27(2): 361–364.
- Yawn BP, Buchanan GR, Afeniyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. *JAMA* 2014; 312(10): 1033–1048.
- Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med* 1994; 330(23): 1639–1644.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106(25): 3143–3421.
- Toth PP. Cardiology patient page. The “good cholesterol”: high-density lipoprotein. *Circulation* 2005; 111(5): 89–91.
- Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. *Lipids Health Dis* 2017; 16(1): 207.
- Ertek S. High-density lipoprotein (HDL) dysfunction and the future of HDL. *Curr Vasc Pharmacol* 2018; 16(5): 490–498.
- Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. *BMJ* 2014; 349: 4379.
- Helvacı MR, Abyad A, Pocock L. What a low prevalence of diabetes mellitus between the most desired values of high density lipoproteins in the plasma. *World Family Med* 2020; 18(7): 25–31.
- Conway J. Hemodynamic aspects of essential hypertension in humans. *Physiol Rev* 1984; 64(2): 617–660.
- Folkow B. Physiological aspects of primary hypertension. *Physiol Rev* 1982; 62(2): 347–504.
- Helvacı MR, Yaprak M, Abyad A, Pocock L. Body weight and blood pressure. *Middle East J Nursing* 2020; 14(2): 22–27.
- Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. *Health Technol Assess* 2003; 7(31): 1–94.
- Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. *Intern Med* 1999; 38(2): 202–206.
- Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999; 19(4): 972–978.
- Zhou B, Wu Y, Yang J, Li Y, Zhang H, Zhao L. Overweight is an independent risk factor for cardiovascular disease in Chinese populations. *Obes Rev* 2002; 3(3): 147–156.

26. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases--report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. *Biomed Environ Sci* 2002; 15(3): 245-252.
27. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med* 1999; 341(15): 1097-1105.
28. Tonkin AM. The metabolic syndrome(s)? *Curr Atheroscler Rep* 2004; 6(3): 165-166.
29. Helvaci MR, Aydin LY, Maden E, Aydin Y. What is the relationship between hypertriglyceridemia and smoking? *Middle East J Age and Ageing* 2011; 8(6).
30. Helvaci MR, Abyad A, Pocock L. The safest upper limit of triglycerides in the plasma. *World Family Med* 2020; 18(1): 16-22.
31. Parfrey NA, Moore W, Hutchins GM. Is pain crisis a cause of death in sickle cell disease? *Am J Clin Pathol* 1985; 84(2): 209-212.
32. Helvaci MR, Aydogan F, Sevinc A, Camci C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. *Pren Med Argent* 2014; 100(1): 49-56.
33. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. *N Engl J Med* 2000; 342(2): 83-89.
34. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. *J Pediatr* 1992; 120(3): 360-366.
35. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. *Cooperative Study of Sickle Cell Disease. Pediatrics* 1989; 84(3): 500-508.
36. Helvaci MR, Arslanoglu Z, Davran R, Duru M, Abyad A, Pocock L. Some signals of death in sickle cell diseases. *Middle East J Intern Med* 2020; 12(1): 17-21.
37. Helvaci MR, Arslanoglu Z, Davran R, Duru M, Abyad A, Pocock L. Deaths in sickle cell diseases may not be sudden unexpected events. *Middle East J Intern Med* 2020; 12(1): 22-28.
38. Hutchinson RM, Merrick MV, White JM. Fat embolism in sickle cell disease. *J Clin Pathol* 1973; 26(8): 620-622.
39. Helvaci MR, Davran R, Abyad A, Pocock L. What a high prevalence of rheumatic heart disease in sickle cell patients. *World Family Med* 2020; 18(9): 80-85.
40. Helvaci MR, Aydin Y, Ayyildiz O. Hydroxyurea may prolong survival of sickle cell patients by decreasing frequency of painful crises. *HealthMED* 2013; 7(8): 2327-2332.
41. Davies SC, Luce PJ, Win AA, Riordan JF, Brozovic M. Acute chest syndrome in sickle-cell disease. *Lancet* 1984; 1(8367): 36-38.
42. Helvaci MR, Kaya H, Sevinc A, Camci C. Body weight and white coat hypertension. *Pak J Med Sci* 2009; 25(6): 916-921.
43. Helvaci MR, Abyad A, Pocock L. High and low density lipoproteins may be negative acute phase proteins of the metabolic syndrome. *Middle East J Nursing* 2020; 14(1): 10-16.
44. Helvaci MR, Arslanoglu Z, Abyad A, Pocock L. Sickle cell diseases are precirrhotic conditions. *Middle East J Intern Med* 2020; 12(1): 10-16.